Loading...
XASX
HXL
Market cap1mUSD
Oct 24, Last price  
0.01AUD
Name

Hexima Ltd

Chart & Performance

D1W1MN
XASX:HXL chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
20.73%
Rev. gr., 5y
%
Revenues
0k
-100.00%
0003,252,0874,440,0864,801,6272,254,2371,806,5231,737,146797,67988,1844,082,0295,810,7081,484,7590
Net income
-934k
L-51.33%
-3,029,909-11,276,023-6,118,978-2,849,898-2,427,859-2,082,307-1,939,008-1,856,202-1,951,228-2,895,532-3,625,762-6,873,646-10,020,761-1,918,886-933,873
CFO
-162k
L-90.82%
000-2,859,602-2,534,264-1,649,372-1,445,354-1,124,755-2,189,537-1,628,595-2,096,512-5,792,242-9,756,275-1,763,285-161,901

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company's lead drug candidate is the plant defensin, pezadeftide, which is in phase IIb clinical trials for the treatment of fungal toenail infections in Australia and New Zealand. Hexima Limited was incorporated in 1997 and is based in Preston, Australia.
IPO date
Dec 01, 2020
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT